Guanfacine Tablet, Extended Release
Product Images NDC 72162-1801

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Guanfacine (NDC 72162-1801). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721621801)

Label for Guanfacine Extended-Release Tablets USP, 4 mg strength, oral tablet dosage form. The label indicates the product contains 4 mg of Guanfacine as Guanfacine Hydrochloride per extended-release tablet. It is packaged with 100 tablets, labeled by Bryant Ranch Prepack and manufactured by Ohm Laboratories Inc. The NDC code 72162-1801-1 and storage instructions are also shown.*

FDA Label Image

Spl-fig-1 (Spl Fig 1)

A line graph comparing plasma concentration of guanfacine over 24 hours. The x-axis shows time in hours, and the y-axis shows guanfacine plasma concentration in ng/mL. Two lines represent guanfacine extended-release tablets at 1 mg once daily and Tenex 1 mg once daily, with the Tenex line peaking higher and faster than the extended-release tablets.*

FDA Label Image

Spl-fig-2 (Spl Fig 2)

A forest plot chart illustrating pharmacokinetic (PK) changes in Cmax and AUC of Guanfacine extended-release tablets when co-administered with CYP3A4 inhibitors (Ketoconazole), CYP3A4 inducers (Rifampin), Oral Methylphenidate, and Lisdexamfetamine Dimesylate. The x-axis represents fold change relative to reference, with data points and confidence intervals shown for each drug interaction.*

FDA Label Image

Spl-fig-3 (Spl Fig 3)

A pharmacokinetic chart showing fold change and 90% confidence intervals in Cmax and AUC for Guanfacine when co-administered with Oral Methylphenidate and Lisdexamfetamine Dimesylate. The x-axis represents change relative to reference, ranging from 0.0 to 2.0, with a vertical line at 1.0 as the reference point.*

FDA Label Image

Spl-fig-4 (Spl Fig 4)

A Kaplan-Meier survival curve depicting treatment failure percentages over time (days) comparing two groups: Placebo (solid line) and SPD503 (dashed line). The x-axis shows time to treatment failure in days, and the y-axis presents treatment failure percentage from 0% to 100%, showing differences in failure rates between the two treatments over approximately 200 days.*

FDA Label Image

Spl-structure (Spl Structure)

Chemical structure of Guanfacine hydrochloride (HCl) showing the arrangement of atoms including chlorine (Cl) substituents, carbonyl, and guanidine groups as depicted in the molecular diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.